Chemical carcinogen safety testing: OECD expert group international consensus on the development of an integrated approach for the testing and assessment of chemical non-genotoxic carcinogens

被引:0
作者
Miriam N. Jacobs
Annamaria Colacci
Raffaella Corvi
Monica Vaccari
M. Cecilia Aguila
Marco Corvaro
Nathalie Delrue
Daniel Desaulniers
Norman Ertych
Abigail Jacobs
Mirjam Luijten
Federica Madia
Akiyoshi Nishikawa
Kumiko Ogawa
Kiyomi Ohmori
Martin Paparella
Anoop Kumar Sharma
Paule Vasseur
机构
[1] Public Health England,Centre for Radiation, Chemical and Environmental Hazards (CRCE)
[2] Regional Agency for Prevention,Center for Environment, Prevention and Health
[3] Environment and Energy Emilia Romagna Region (Arpae),German Centre for the Protection of Laboratory Animals (Bf3R)
[4] European Commission Joint Research Centre (EC JRC),Division of Medical Biochemistry, Biocenter
[5] US Food and Drug Administration (FDA),undefined
[6] Corteva Agriscience,undefined
[7] Organisation for Economic Cooperation and Development (OECD),undefined
[8] Health Canada,undefined
[9] German Federal Institute for Risk Assessment,undefined
[10] National Institute for Public Health and the Environment (RIVM),undefined
[11] National Institute of Health Sciences,undefined
[12] Kanagawa Prefectural Institute of Public Health,undefined
[13] Medical University of Innsbruck,undefined
[14] Technical University of Denmark,undefined
[15] CNRS University de Lorraine,undefined
来源
Archives of Toxicology | 2020年 / 94卷
关键词
Non-genotoxic carcinogenicity; Integrated approaches to testing and assessment; IATA; Cancer hallmarks; Hazard assessment; Cancer prevention; Cancer model; Cancer microenvironment;
D O I
暂无
中图分类号
学科分类号
摘要
While regulatory requirements for carcinogenicity testing of chemicals vary according to product sector and regulatory jurisdiction, the standard approach starts with a battery of genotoxicity tests (which include mutagenicity assays). If any of the in vivo genotoxicity tests are positive, a lifetime rodent cancer bioassay may be requested, but under most chemical regulations (except plant protection, biocides, pharmaceuticals), this is rare. The decision to conduct further testing based on genotoxicity test outcomes creates a regulatory gap for the identification of non-genotoxic carcinogens (NGTxC). With the objective of addressing this gap, in 2016, the Organization of Economic Cooperation and Development (OECD) established an expert group to develop an integrated approach to the testing and assessment (IATA) of NGTxC. Through that work, a definition of NGTxC in a regulatory context was agreed. Using the adverse outcome pathway (AOP) concept, various cancer models were developed, and overarching mechanisms and modes of action were identified. After further refining and structuring with respect to the common hallmarks of cancer and knowing that NGTxC act through a large variety of specific mechanisms, with cell proliferation commonly being a unifying element, it became evident that a panel of tests covering multiple biological traits will be needed to populate the IATA. Consequently, in addition to literature and database investigation, the OECD opened a call for relevant assays in 2018 to receive suggestions. Here, we report on the definition of NGTxC, on the development of the overarching NGTxC IATA, and on the development of ranking parameters to evaluate the assays. Ultimately the intent is to select the best scoring assays for integration in an NGTxC IATA to better identify carcinogens and reduce public health hazards.
引用
收藏
页码:2899 / 2923
页数:24
相关论文
共 236 条
[1]  
Aarts JM(1995)Species-specific antagonism of Ah receptor action by 2,2',5,5'-tetrachloro- and 2,2',3,3'4,4'-hexachlorobiphenyl Eur J Pharmacol 293 463-474
[2]  
Denison MS(2011)Alternative (non-animal) methods for cosmetics testing: current status and future prospects-2010 Arch Toxicol 85 367-485
[3]  
Cox MA(2011)A critical review of the effectiveness of rodent pharmaceutical carcinogenesis testing in predicting for human risk Vet Pathol 48 772-784
[4]  
Adler S(2010)Adverse outcome pathways: a conceptual framework to support ecotoxicology research and risk assessment Environ Toxicol Chem 29 730-741
[5]  
Basketter D(2009)Molecular mechanism and clinical implications of endocrine therapy resistance in breast cancer Oncology 77 23-37
[6]  
Creton S(2016)Inflammatory bowel disease and cancer: the role of inflammation, immunosuppression, and cancer treatment World J Gastroenterol 22 4794-4801
[7]  
Alden CL(2018)Recommendation on test readiness criteria for new approach methods in toxicology: exemplified for developmental neurotoxicity Altex 35 306-352
[8]  
Lynn A(2019)Validation of in vitro methods for human cytochrome P450 enzyme induction: Outcome of a multi-laboratory study Toxicol In Vitro 60 212-228
[9]  
Bourdeau A(2010)Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm Nat Immunol 11 889-896
[10]  
Ankley GT(2016)Classification schemes for carcinogenicity based on hazard-identification have become outmoded and serve neither science nor society Regulat Toxicol Pharmacol 82 158-166